{"disease":{"id":"local-treatment-of-unresectable-melanoma-lesions","name":"local treatment of unresectable melanoma lesions"},"drugs":{"marketed":[{"drug_id":"talimogene-laherparepvec","indication_name":"Local treatment of unresectable melanoma lesions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imlygic","generic_name":"TALIMOGENE LAHERPAREPVEC","company_name":"Amgen","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Imlygic is a genetically modified virus that selectively infects and kills cancer cells, stimulating an anti-tumor immune response."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}